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We report the updated classification of primary immunodeficiencies (PIDs) compiled by the
Expert Committee of the International Union of Immunological Societies. In comparison to
the previous version, more than 30 new gene defects are reported in this updated version.
In addition, we have added a table of acquired defects that are phenocopies of PIDs. For
each disorder, the key clinical and laboratory features are provided.This classification is the
most up-to-date catalog of all known PIDs and acts as a current reference of the knowl-
edge of these conditions and is an important aid for the molecular diagnosis of patients
with these rare diseases.
Keywords: primary immunodeficiencies, IUIS, classification, genetic defects, genotype
BACKGROUND
The International Union of Immunological Societies (IUIS)
Expert Committee on Primary Immunodeficiency met in New
York on 19th–21st April 2013 to update the classification of human
primary immunodeficiencies (PIDs). This report represents the
most current and complete catalog of known PIDs. It serves as a
reference for these conditions and provides a framework to help
in the diagnostic approach to patients suspected to have PID.
As in previous reports, we have classified the conditions into
major groups of PIDs and these are now represented in nine dif-
ferent tables. In each table, we list the condition, its genetic defect
if known, and the major immunological and in some conditions
the non-immunological abnormalities associated with the disease.
The classification this year differs slightly from the previous edition
in that Table 1 lists combined immunodeficiencies without non-
immunologic phenotypes, whereas Table 2 refers to combined
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1. T−B+ severe combined immunodeficiency (SCID)





Defect in γ chain of receptors
for IL-2, -4, -7, -9, -15, -21
(b) JAK3
deficiency









Mutation of IL7RA AR Markedly decreased Normal or
increased
Decreased Normal NK cells 146661
Defect in IL-7 receptor α chain
(d) CD45
deficiencya




Mutation of CD3D AR Markedly decreased Normal Decreased Normal NK cells 186790





Mutation of CD3E AR Markedly decreased Normal Decreased Normal NK cells 186830





Mutation of CD3Z AR Markedly decreased Normal Decreased Normal NK cells 186740






defective thymic egress of T
cells and defective T cell
locomotion
AR Markedly decreased Normal Decreased Detectable thymus




(i) DNA recombination defects
(a) RAG 1
deficiency





activating gene (RAG) 1
(a) RAG 2
deficiency









Mutation of ARTEMIS AR Markedly decreased Markedly
decreased
Decreased Radiation sensitivity 602450
Defective VDJ recombination;




Mutation of PRKDC -
Defective VDJ recombination;
defect in DNA PKcs
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may lead to delayed or
milder presentation
102700
Combined immunodeficiencies generally less profound than severe combined immunodeficiency
3. CD40 ligand
deficiency
Mutation of CD40LG defects
in CD40 ligand (CD40L; also


























Mutation of CD40 (also called























Mutation of PNP, absent PNP,
and T cell and neurologic













Mutation of CD3G defect in
CD3 γ – component of the T
cell antigen receptor complex





Mutation of CD8A, defects of
CD8 α chain – important for
maturation and function of
CD8 T cells







acts downstream of TCR
AR Decreased CD8,
normal CD4 cells
Normal Normal Autoimmunity in
some cases
269840
9. MHC class I
deficiency
Mutations in TAP1, TAP2, or
TAPBP (tapasin) genes giving
MHC class I deficiency
AR Decreased CD8,
normal CD4






factors for MHC class II














Mutations in ITK encoding
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encoding an adaptor protein
regulating intracellular signals






















Mutations in RMRP (RNase
MRP RNA) involved in
processing of mitochondrial
RNA and cell cycle control





















impaired Mg++ flux leading to
impaired TCR signaling
XL Decreased CD4 cells
reduced numbers of
RTE, impaired T cell
proliferation in
response to CD3











































Low naïve T cells




















and impaired T cells
proliferation
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Mutations in TRAC – essential
component of the T cell
receptor
AR Normal all CD3 T
cells expressed
TCRγδ (or may be













Defects in LCK – a proximal




















Mutations in MALT1 – a
caspase-like cysteine protease
that is essential for nuclear
factor kappa B activation
AR Normal impaired T
cells proliferation








Defects in IL-21R – together
with common gamma chain
binds IL-21
















Defects in UNC119 – an
activator of src tyrosine
kinases










Defects in CARD11 – acts as a


















Defects in OX40 – a
co-stimulatory molecule
expressed on activated T cells
















Defects in IKBKB – encodes
IkB kinase 2 a component of
the NF-κB pathway
AR Normal total T cells;
absent regulatory














Mutation in PIK3CD, PI3K-δ AD
gain-of-function
Decreased total
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AR Normal or decreased
















Mutations in CD27, encoding
TNF-R member superfamily
required for generation and
long-term maintenance of T
cell immunity


















RAG1, RAG2, artemis, IL7RA,
RMRP, ADA, DNA ligase IV,
IL-2RG, AK2, or associated
with DiGeorge syndrome;















XL, X-linked inheritance; AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; SCID, severe combined immune deficiencies; EBV, Epstein–Barr
virus; Ca++, calcium; MHC, major histocompatibility complex, RTE, recent thymic emigrants, HPV, human papillomavirus.
aTen or fewer unrelated cases reported in the literature.
Infants with SCID who have maternal T cells engraftment may have T cells that do not function normally; these cells may cause autoimmune cytopenias or graft
versus host disease. Hypomorphic mutations in several of the genes that cause SCID may result in Omenn syndrome (OS), or “leaky” SCID or a less profound
CID phenotype. Both OS and leaky SCID can be associated with higher numbers of T cells and reduced rather than absent activation responses when compared
with typical SCID caused by null mutations. A spectrum of clinical findings including typical SCID, OS, leaky SCID, granulomas with T lymphopenia, autoimmunity,
and CD4+ T lymphopenia can be found with RAG gene defects. RAC2 deficiency is a disorder of leukocyte motility and is reported in Table 5; however, one patient
with RAC2 deficiency was found to have absent T cell receptor excision circles (TRECs) by newborn screening, but T cell numbers and mitogen responses were not
impaired. For additional syndromic conditions withT cell lymphopenia, such as DNA repair defects, cartilage hair hypoplasia, IKAROS deficiency, and NEMO syndrome,
see Tables 2 and 6; however, it should be noted that individuals with the most severe manifestations of these disorders could have clinical signs and symptoms of
SCID. Severe folate deficiency (such as with malabsorption due to defects in folate carrier or transporter genes SLC10A1 or PCFT) and some metabolic disorders,
such as methylmalonic aciduria, may present with reversible profound lymphopenia in addition to their characteristic presenting features.
immunodeficiencies with syndromic features, as increasing num-
bers of these are being identified. The title and classification of
Tables 3–8 present the same major PID groups as in the previous
report.
In this updated version, we have added a new category in
Table 9 in which “Phenocopies of PID” are listed. This has resulted
from our understanding and study of conditions that present as
inherited immunodeficiencies, but which are not due to germline
mutations and instead arise from acquired mechanisms. Examples
include somatic mutations in specific immune cell populations
that give rise to the phenotype of autoimmune lymphoprolifer-
ative syndrome (ALPS), and also autoantibodies against specific
cytokines or immunological factors, with depletion of these factors
leading to immunodeficiency. It is likely that increasing numbers
of PID phenocopies will be identified in the future, and this may
be the start of a much longer table.
As with all complex diseases, any classification cannot be strictly
adhered to. Certain conditions fall into more than one category
and so appear in more than one table. For example, CD40L ligand
deficiency is reported in both Tables 1 and 3 as it was initially
identified as a defect of B cell isotype switching but is now known
to be a defect of co-stimulatory T cell help and function. Similarly,
XLP1 due to defects in SH2D1A is listed in Table 1 – combined
immunodeficiencies, due to defects of T cell cytotoxicity, T cell
help, and B cell maturation, but also in Table 4 – diseases of
immune dysregulation, due to the susceptibility to hemophago-
cytosis. There is a growing appreciation that there can be wide
phenotypic viability within a specific genotype that is a prod-
uct of varied specific mutations between different patients as well
as other host and/or environmental factors. The complexities of
these conditions in terms of clinical and immunological presen-
tation and heterogeneity cannot be easily captured in the limited
space of a table format. For this reason, the furthest left column
contains the Online Mendelian Inheritance in Man (OMIM) ref-
erence for each condition to allow access to greater detail and
updated information.
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2. DNA repair defects (other than those inTable 1)
(a) Ataxia–
telangiectasia
Mutations in ATM ; disorder of















































NBS1 (Nibrin); disorder of cell


























Mutations in BLM ; RecQ-like
helicase
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Mutations in ZBTB24 (ICF2) AR Decreased or
normal; responses























Mutations in PMS2, resulting
in class switch recombination
deficiency due to impaired
mismatch repair


















resulting in defective DNA
double-strand break repair
AR Normal Normal Low IgG or
low IgA
Short stature; mild














component 4) gene involved in
DNA replication and repair





3. Thymic defects with additional congenital anomalies
(a) DiGeorge
anomaly
Contiguous gene defect in
90% affecting thymic
development; may also be due
















deletion (3 Mb) in
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Variable defects of the thymus
and associated T cell
abnormalities often due to
deletions or mutations in




















Mutations in RMRP (RNase
MRP RNA) involved in
processing of mitochondrial
RNA and cell cycle control



































present as SCID; bone
marrow failure
242900
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6. Dyskeratosis congenital (DKC)































Mutation in NOLA3 (NOP10
PCFT)
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7. Defects of vitamin B12 and folate metabolism
(a) TCN2
deficiency
Mutation in TCN2; encodes
transcobalamin, a transporter
of cobalamin into blood cells
























essential for processing of
single-carbon folate
derivatives







Mutations in SPINK5 resulting
in lack of the serine protease
inhibitor LEKTI, expressed in
epithelial cells


















Defects in forkhead box N1
transcription factor encoded
by FOXN1
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Mutations in STIM1, a stromal
interaction molecule 1














Mutations in STAT5B, signal
transducer, and transcription
factor, essential for normal
signaling from IL-2 and 15, key
growth factors for T and NK
cells



















































Mutation in POLE1; defective
DNA replication










































SCID, severe combined immune deficiencies; XL, X-linked inheritance; AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; MSMD, Mendelian
susceptibility of mycobacterial disease.
aTen or fewer unrelated cases reported in the literature.
T and B cell number and function in these disorders exhibit a wide range of abnormality; the most severely affected cases meet diagnostic criteria for SCID or leaky
SCID and require immune system restoring therapy such as allogeneic hematopoietic cell transplantation. While not all DOCK8-deficient patients have elevated serum
IgE, most have recurrent viral infections and malignancies as a result of combined immunodeficiency. AR-HIES due toTyk2 deficiency is also listed inTable 6, because
of its association with atypical mycobacterial disease resulting in MSMD. Riddle syndrome is caused by mutations in a gene involved in DNA double-strand break
repair and is associated with hypogammaglobulinemia. Autosomal dominant and autosomal recessive forms of dyskeratosis congenita are included in this table.
IKAROS-deficiency represents a single prematurely born infant who died at the age of 87 days and who had absent B and NK cells and non-functional T cells.
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Table 3 | Predominantly antibody deficiencies.
Disease Genetic defect/
presumed pathogenesis
Inheritance Serum Ig Associated features OMIM
number
1. Severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells
(a) BTK deficiency Mutations in BTK, a cytoplasmic
tyrosine kinase activated by
crosslinking of the BCR
XL All isotypes decreased in




normal numbers of pro-B cells
300300
(b) µ Heavy chain
deficiency
Mutations in µ heavy chain;
essential component of the
pre-BCR
AR All isotypes decreased Severe bacterial infections;
normal numbers of pro-B cells
147020
(c) λ5 Deficiencya Mutations in l5; part of the
surrogate light chain in the
pre-BCR
AR All isotypes decreased Severe bacterial infections;
normal numbers of pro-B cells
146770
(d) Igα deficiencya Mutations in Iga (CD79a); part of
the pre-BCR and BCR
AR All isotypes decreased Severe bacterial infections;
normal numbers of pro-B cells
112205
(e) Igβ deficiencya Mutations in Igb (CD79β); part of
the pre-BCR and BCR
AR All isotypes decreased Severe bacterial infections;
normal numbers of pro-B cells
147245
(f) BLNK deficiencya Mutations in BLNK ; a scaffold
protein that binds to BTK
AR All isotypes decreased Severe bacterial infections;




Mutations in PIK3R1; a kinase
involved in signal transduction in
multiple cell types
AR All isotypes decreased Severe bacterial infections;




Mutations in TCF3; a
transcription factor required for
control of B cell development




May have monosomy 7, trisomy
8, or dyskeratosis congenita
Variable One or more isotypes may
be decreased










decreased number of pro-B cells
Not
assigned




Unknown Variable Low IgG and IgA and/or
IgM
Clinical phenotypes vary: most







(b) ICOS deficiencya Mutations in ICOS; a
co-stimulatory molecule
expressed on T cells






(c) CD19 deficiencya Mutations in CD19;
transmembrane protein that
amplifies signal through BCR
AR Low IgG and IgA and/or
IgM
Recurrent infections; may have
glomerulonephritis
107265
(d) CD81 deficiencya Mutations in CD81;
transmembrane protein that
amplifies signal through BCR
AR Low IgG, low or normal
IgA and IgM
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Table 3 | Continued
Disease Genetic defect/
presumed pathogenesis
Inheritance Serum Ig Associated features OMIM
number
(e) CD20 deficiencya Mutations in CD20; a B cell
surface receptor involved in B
cell development and plasma cell
differentiation
AR Low IgG, normal or
elevated IgM and IgA
Recurrent infections 112210
(f) CD21 deficiencya Mutations in CD21; also known
as complement receptor 2 and
forms part of the CD19 complex




(g) TACI deficiency Mutations in TNFRSF13B (TACI);
a TNF receptor family member
found on B cells and is a
receptor for BAFF and APRIL
AD or AR or
complex
Low IgG and IgA and/or
IgM
Variable clinical expression 604907
(h) LRBA deficiency Mutations in LRBA
(lipopolysaccharide responsive
beige-like anchor protein)









(BAFF-R); a TNF receptor family
member found on B cells and is
a receptor for BAFF
AR Low IgG and IgM Variable clinical expression 606269









Mutations in NFKB2; an
essential component of the
non-canonical NF-κB pathway













Reduced B cell number
Hypogammaglobulinemia
193670
3. Severe reduction in serum IgG and IgA with normal/elevated IgM and normal numbers of B cells
(a) CD40L deficiency Mutations in CD40LG (also
called TNFSF5 or CD154)
XL IgG and IgA decreased;
IgM may be normal or
increased; B cell numbers






(b) CD40 deficiencya Mutations in CD40 (also called
TNFRSF5 )






(c) AID deficiency Mutations in AICDA gene AR IgG and IgA decreased;
IgM increased
Bacterial infections, enlarged
lymph nodes, and germinal
centers
605257
(d) UNG deficiency Mutations in UNG AR IgG and IgA decreased;
IgM increased
Enlarged lymph nodes and
germinal centers
191525
4. Isotype or light chain deficiencies with generally normal numbers of B cells





AR One or more IgG and/or
IgA subclasses as well as
IgE may be absent
May be asymptomatic Not
assigned
(Continued)
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Table 3 | Continued
Disease Genetic defect/
presumed pathogenesis




Mutations in Kappa constant
gene





Unknown Variable Reduction in one or more
IgG subclass
Usually asymptomatic; a
minority may have poor antibody





(d) IgA with IgG
subclass deficiency
Unknown Variable Reduced IgA with
decrease in one or more
IgG subclass




Mutation in PRKCD; encoding a
member of the protein kinase C
family critical for regulation of
cell survival, proliferation, and
apoptosis
AR Low IgG levels; IgA and




















Unknown Variable IgA decreased/absent Usually asymptomatic; may have
recurrent infections with poor
antibody responses to
carbohydrate antigens; may have
allergies or autoimmune disease.
A very few cases progress to







numbers of B cells
Unknown Variable Normal Reduced ability to produce







numbers of B cells
Unknown Variable IgG and IgA decreased Normal ability to produce
antibodies to vaccine antigens,




XL, X-linked inheritance; AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; BTK, Bruton tyrosine kinase; BLNK, B cell linker protein; AID,
activation-induced cytidine deaminase; UNG, uracil-DNA glycosylase; ICOS, inducible costimulator; Ig(κ), immunoglobulin or κ light chain type.
aTen or fewer unrelated cases reported in the literature.
Several autosomal recessive disorders that might previously have been called CVID have been added to Table 3. CD81 is normally co-expressed with CD19 on the
surface of B cells. As for CD19 mutations, mutations in CD81 result in normal numbers of peripheral blood B cells, low serum IgG, and an increased incidence of
glomerulonephritis. Single patient with a homozygous mutation in CD20 and CD21 has been reported.
Common variable immunodeficiency disorders (CVID) include several clinical and laboratory phenotypes that may be caused by distinct genetic and/or environ-
mental factors. Some patients with CVID and no known genetic defect have markedly reduced numbers of B cells as well as hypogammaglobulinemia. Alterations
in TNFRSF13B (TACI) and TNFRSF13C (BAFF-R) sequences may represent disease-modifying mutations rather than disease causing mutations. CD40L and CD40
deficiency are included in Table 1 as well as this table. A small minority of patients with XLP (Table 4), WHIM syndrome (Table 6), ICF (Table 2), VOD1 (Table 2),
thymoma with immunodeficiency (Good syndrome), or myelodysplasia are first seen by an immunologist because of recurrent infections, hypogammaglobulinemia,
and normal or reduced numbers of B cells. Patients with GATA2 mutations (Table 5) may have markedly reduced numbers of B cells, as well as decreased monocytes
and NK cells, and a predisposition to myelodysplasia but they do not usually have an antibody deficiency.
www.frontiersin.org April 2014 | Volume 5 | Article 162 | 15
Al-Herz et al. PID IUIS classification













1. Familial hemophagocytic lymphohistiocytosis (FHL) syndromes




Mutations in PRF1; perforin

















Mutations in UNC13D a;










































































encoding a GTPase that
promotes docking of
secretory vesicles to the
cell membrane











Mutations in AP3B1 gene,
encoding for the b subunit
of the AP-3 complex


























NK cell and CTL
cytotoxic activity
Clinical and immunological
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Mutations in ITK encoding


















maintenance of T cell
immunity
AR Normal No memory
B cells
Low T and NK cells
functions
Clinical and immunological















encoding a T cell
transcription factor































signaling from IL-2 and 15,
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Mutations in ITCH, an E3
ubiquitin ligase catalyzes
the transfer of ubiquitin to
a signaling protein in the
cell including
phospholipase Cγ1 (PLCγ1)





















5. Autoimmune lymphoproliferative syndrome (ALPS)


















ARc Increased lymphoma risk
IgG and A normal or
increased




Mutations in TNFSF6, Fas






























































GOF mutations in CARD11,
encoding a protein required
for antigen
receptor–induced NF-κB








in B & T
Lymphoproliferation 606445







encoding a member of the
protein kinase C family
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in clearing cellular nucleic
debris


























involves in clearing cellular
nucleic debris























involves in clearing cellular
nucleic debris























involves in clearing cellular
nucleic debris
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XL, X-linked inheritance; AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; FHL, familial hemophagocytic lymphohistiocytosis; HLH, hemo-
phagocytic lymphohistiocytosis; HSMG, hepatosplenomegaly; DN, double negative; SLE, systemic lupus erythematous; IBD, inflammatory bowel disease; CSF,
chronic cerebrospinal fluid.
aTen or fewer unrelated cases reported in the literature.
bSomatic mutations of TNFRSF6 cause a similar phenotype (ALPS–sFAS), see Table 9. Germinal mutation and somatic mutation of TNFRSF6 can be associated in
some ALPS–FAS patients.
cAR ALPS–FAS patients have a most severe clinical phenotype.
dSomatic mutations in KRAS or NRAS can give this clinical phenotype associated autoimmune leukoproliferative disease (RALD) and are now included in Table 9
entitled phenocopies of PID.
eDe novo dominant TREX1 mutations have been reported.
Fourteen new disorders have been added to Table 4. Two new entries have been added in the table, including immune dysregulation with colitis and Type 1
interferonopathies. EBV-driven lymphoproliferation is also observed in MAGT1 deficiency (Table 1).


















Susceptibility to MDS/leukemia 202700
(b) SCN2a (GFI 1
deficiency)
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defects in patients with defects





Mutation in G6PC3: abolished
enzymatic activity of glucose-
6-phosphatase, aberrant
glycosylation, and enhanced







ear deafness, and venous
angiectasias of trunks and limbs
612541






















(g) Cyclic neutropenia Mutation in ELANE : misfolded
protein response






Mutation in WAS: regulator of



















(j) Barth syndrome Mutation in tafazzin (TAZ)






















Poikiloderma, neutropenia, MDS 613276
























Mild LAD type 1 features plus













LAD type 1 plus bleeding
tendency
612840
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(e) β-Actin deficiencya Mutation in ACTB:
cytoplasmic actin













Mutation in CTSC : cathepsin
C activation of serine
proteases
AR N+M Chemotaxis Periodontitis, palmoplantar




Mutation in C/EBPE : myeloid
transcription factor
AR N Chemotaxis Neutrophils with bilobed nuclei;





Mutation in SBDS: defective
ribosome synthesis








Mutation in CYBB: electron
transport protein (gp91phox)
XL N+M Killing (faulty O−2
production)
Recurrent bacterial infection,
susceptibility to fungal infection,
inflammatory gut
manifestations McLeod
phenotype in patients with




recessive CGD – p22
phox deficiency
Mutation in CYBA: electron
transport protein (p22phox)
AR N+M Killing (faulty O−2
production)
Recurrent bacterial infection,





recessive CGD – p47
phox deficiency
Mutation in NCF1: adapter
protein (p47phox)
AR N+M Killing (faulty O−2
production)
Recurrent bacterial infection,





recessive CGD – p67
phox deficiency
Mutation in NCF2: activating
protein (p67phox)
AR N+M Killing (faulty O−2
production)
Recurrent bacterial infection,





recessive CGD – p40
phox deficiencya
Mutation in NCF4: activating
protein (p40phox)





4. Mendelian susceptibility to mycobacterial disease (MSMD)
(a) IL-12 and IL-23
receptor β1 chain
deficiency
Mutation in IL-12RB1: IL-12 and
IL-23 receptor β1 chain
AR L+NK IFN-γ secretion Susceptibility to Mycobacteria
and Salmonella
209950
(b) IL-12p40 deficiency Mutation in IL-12B: subunit
p40 of IL-12/IL-23
AR M IFN-γ secretion Susceptibility to Mycobacteria
and Salmonella
161561
(c) IFN-γ receptor 1
deficiency
Mutation in IFNGR1: IFN-γR
ligand binding chain





(d) IFN-γ receptor 2
deficiency
Mutation in IFNGR2: IFN-γR
accessory chain





Mutation in STAT1 (loss of
function)
AD M+L IFN-γ signaling Susceptibility to Mycobacteria 600555
(Continued)
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Mutation in CYBB: electron
transport protein (gp 91 phox)







Mutation in IRF8 : IL-12






Susceptibility to Mycobacteria 601565














































XL, X-linked inheritance; AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; ACTB, actin beta; B, B lymphocytes; CEBPE, CCAAT/enhancer-
binding protein epsilon; CMML, chronic myelomonocytic leukemia; CTSC, cathepsin C; CYBA, cytochrome b alpha subunit; CYBB, cytochrome b beta subunit;
DC, dendritic cells; ELANE, elastase neutrophil-expressed; GATA2, GATA binding protein 2; IFN, interferon; IFNGR1, interferon-gamma receptor subunit 1; IFNGR2,
interferon-gamma receptor subunit 2; IL-12B, interleukin-12 beta subunit; IL-12RB1, interleukin-12 receptor beta 1; IFR8, interferon regulatory factor 8; F, fibroblasts;
FPR1, formylpeptide receptor 1; FUCT1, fucose transporter 1; GFI1, growth factor independent 1; HAX1, HLCS1-associated protein X1; ITGB2, integrin beta-2; L,
lymphocytes; M, monocytes–macrophages; MDC, myeloid dendritic cells; MDS, myelodysplasia; Mel, melanocytes; Mφ, macrophages; MSMD, Mendelian suscepti-
bility to mycobacterial disease; N, neutrophils; NCF1, neutrophil cytosolic factor 1; NCF2, neutrophil cytosolic factor 2; NCF4, neutrophil cytosolic factor 4; NK, natural
killer cells; ROBLD3: roadblock domain containing 3; SBDS, Shwachman–Bodian–Diamond syndrome; STAT, signal transducer and activator of transcription.
aTen or fewer unrelated cases reported in the literature.
Table 5 includes seven newly described genetic defects of phagocyte number and/or function including Barth syndrome, Cohen syndrome, and poikiloderma with
neutropenia. In these three clinically well-known diseases, the genetic defects have been elucidated, although their molecular pathogenesis remains ill-defined. A
new cause of autosomal recessive chronic granulomatous disease, namely a deficiency of the cytosolic activating protein p40 phox, has now been found in two
CGD patients and is included under defects of respiratory burst. Under the heading of Mendelian susceptibility of mycobacterial disease (MSMD), two new entities
were added: (a) a subgroup of X-linked gp91 phox deficiency with isolated susceptibility to mycobacteria and a defect of the respiratory burst in macrophages only;
(b) an autosomal dominant form of IRF8-deficiency, resulting from a lack of CD1c+ myeloid dendritic cells that would normally secrete IL-12. The clinical phenotype
of MSMD may vary, depending on the nature of the genetic defect. Finally, GATA2 deficiency was recently identified as the cause of the Mono MAC syndrome,
with multilineage cytopenias (of monocytes, peripheral dendritic cells, NK- and B-lymphocytes) resulting in opportunistic infections (including mycobacteria), alveolar
proteinosis, and malignancy.
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Table 6 | Defects in innate immunity.
Disease Genetic defect/
presumed pathogenesis







































2. TIR signaling pathway deficiency
(a) IRAK-4 deficiency Mutations of IRAK-4, a












Mutations of MYD88, a











































Reduced B cell number
Hypogammaglobulinemia
5. Epidermodysplasia verruciformis
EVER1 deficiency Mutations of EVER1 AR Keratinocytes
and leukocytes
EVER proteins may




HPV (group B1) infections and
cancer of the skin (typical EV)
226400
EVER2 deficiency Mutations of EVER2 AR Keratinocytes
and leukocytes
EVER proteins may




HPV (group B1) infections and
cancer of the skin (typical EV)
226400
6. Predisposition to severe viral infection
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Table 6 | Continued
Disease Genetic defect/
presumed pathogenesis











7. Herpes simplex encephalitis (HSE)





TLR3-dependent Herpes simplex virus 1
encephalitis (incomplete
clinical penetrance for all
etiologies listed here)
613002









UNC-93B-dependent Herpes simplex virus 1
encephalitis
610551




(c) Mutations of TRAF3 AD CNS resident
cells and
fibroblasts
TRAF3-dependent Herpes simplex virus 1
encephalitis
614849
IFN-α, -β, and -λ
induction
(d) TRIF deficiencya (c) Mutations of TRIF AD CNS resident
cells and
fibroblasts
TRIF-dependent Herpes simplex virus 1
encephalitis
614850
AR IFN-α, -β, and -λ
induction
(e) TBK1 deficiencya (c) Mutations of TBK1 AD CNS resident
cells and
fibroblasts
TBK1-dependent Herpes simplex virus 1
encephalitis
Not
assignedIFN-α, -β, and -λ
induction
8. Predisposition to invasive fungal diseasesa







9. Chronic mucocutaneous candidiasis (CMC)
(a) IL-17RA
deficiencya





























(d) ACT1 deficiencya (c) Mutations in ACT1 AR T cells,
fibroblasts
Fibroblasts fail to
respond to IL-17A and





10. Trypanosomiasisa Mutations in APOL-I AD APOL-I Trypanosomiasis 603743
(Continued)
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Table 6 | Continued
Disease Genetic defect/
presumed pathogenesis







Mutations in RPSA AD Spleen RPSA encodes
ribosomal protein SA,
a component of the






XL, X-linked inheritance; AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; NF-κB, nuclear factor kappa B;TIR,Toll and interleukin 1 receptor;
IFN, interferon; HVP, human papilloma virus; TLR, Toll-like receptor; IL, interleukin.
aTen or fewer unrelated cases reported in the literature.
Eight new disorders have been added to Table 6. Three new entries have been added in the table. One is a new PID with the association of recurrent bacterial
infections, autoinflammation, and amylopectinosis caused by AR HOIL1 mutations found in two kindreds.The second is severe viral infection, for which three genetic
etiologies have been discovered. AR-STAT2 deficiency and AR-CD16 deficiency have been found in one kindred each. AR MCM4 deficiency has been found in several
Irish kindreds. The third is isolated congenital asplenia identified in 18 patients from 8 kindreds.
XR-EDA-ID is highly heterogeneous clinically, both in terms of developmental features (some patients display osteopetrosis and lymphedema, in addition to EDA,
while others do not display any developmental features) and infectious diseases (some display multiple infections, viral, fungal, and bacterial, while others display a
single type of infection). The various OMIM entries correspond to these distinct clinical diseases.











1. Defects effecting the inflammasome
(a) Familial
Mediterranean fever
Mutations of MEFV (lead



























Mutations of MVK (lead to














Mutations of CIAS1 (also
called PYPAF1 or NALP3)
lead to constitutive
activation of the NLRP3
inflammasome
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IL-10 deficiency leads to

















receptor alpha leads to

















receptor beta leads to












Mutations of PSTPIP1 (also
called C2BP1) (affects both






















AD Monocytes Mutations in nucleotide
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11. DIRA (deficiency of
the interleukin 1
receptor antagonist)a














12. DITRA – deficiency
of IL-36 receptor
antagonist





leads to increase IL-8
production
Pustular psoriasis 614204





































17. HOIL1 deficiency Mutation in HOIL1 (see
functional defect)











Mutation in PLCG2 (see
functional defect)








AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; PMN, polymorphonuclear cells; ASC, apoptosis-associated speck-like protein with a cas-
pase recruitment domain; CARD, caspase recruitment domain; CD2BP1, CD2 binding protein 1; PSTPIP1, proline/serine/threonine phosphatase-interacting protein
1; SNHL, sensorineural hearing loss; CIAS1, cold-induced autoinflammatory syndrome 1.
aTen or fewer unrelated cases reported in the literature.
Autoinflammatory diseases are clinical disorders marked by abnormally increased inflammation, mediated predominantly by the cells and molecules of the innate
immune system, with a significant host predisposition. While the genetic defect of one of the most common autoinflammatory conditions, PFAPA, is not known,
recent studies suggest that it is associated with activation of IL-1 pathway and response to IL-1beta antagonists.
Muckle–Wells syndrome, familial cold autoinflammatory syndrome and neonatal onset multisystem inflammatory disease (NOMID), which is also called chronic
infantile neurologic cutaneous and articular syndrome (CINCA) are caused by similar mutations in CIAS1 mutations. The disease phenotype in any individual appears
to depend on modifying effects of other genes and environmental factors.
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Table 8 | Complement deficiencies.
Disease Genetic defect;
presumed pathogenesis
Inheritance Functional defect Associated features OMIM
number
1. C1q deficiency Mutation in C1QA, C1QB,
C1QC : classical complement
pathway components
AR Absent CH50 hemolytic activity,









2. C1r deficiency Mutation in C1R: classical
complement pathway
component
AR Absent CH50 hemolytic activity,





3. C1s deficiency Mutation in C1S: classical
complement pathway
component
AR Absent CH50 hemolytic activity,





4. C4 deficiency Mutation in C4A, C4B: classical
complement pathway
components
AR Absent CH50 hemolytic activity,
defective activation of the
classical pathway, defective
humoral immune response to






5. C2 deficiency Mutation in C2: classical
complement pathway
component
AR Absent CH50 hemolytic activity,





















7. C5 deficiency Mutation in C5 : terminal
complement component




8. C6 deficiency Mutation in C6 : terminal
complement component




9. C7 deficiency Mutation in C7 : terminal
complement component




10. C8 α–γ deficiency Mutation in C8A, C8G: terminal
complement components




11. C8b deficiency Mutation in C8B: Terminal
complement component




12. C9 deficiency Mutation in C9: Terminal
complement component
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Table 8 | Continued
Disease Genetic defect;
presumed pathogenesis





regulation of kinins and
complement activation




Spontaneous activation of the
contact system with generation
of bradykinin from high
molecular weight kininogen
14. Factor Ba Mutation in CFB: activation of
the alternative pathway





Mutation in CFD: regulation of
the alternative complement
pathway
AR Absent AH50 hemolytic activity Neisserial infections 134350
16. Properdin
deficiency
Mutation in CFP : regulation of
the alternative complement
pathway
XL Absent AH50 hemolytic activity Neisserial infections 312060
17. Factor I deficiency Mutation in CFI: regulation of the
alternative complement pathway
AR Spontaneous activation of the
alternative complement pathway










Mutation in CFH : regulation of
the alternative complement
pathway
AR Spontaneous activation of the
alternative complement pathway










Mutation in CFHR1-5 : bind C3b AR Normal CH50, AH50,
autoantibodies to Factor H
aHUS 235400
20. Thrombomodulina Mutation in THBD: regulates
complement and coagulant
activation
AD Normal CH50, AH50 aHUS 188040
21. MASP1 deficiency Mutation in MASP1: cleaves C2
and activates MASP2
AR Deficient activation of the lectin
activation pathway, cell migration
Infections, 3MC syndrome 600521
22. MASP2
deficiencya








Mutation in COLEC11: binds
MASP1, MASP3
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Table 8 | Continued
Disease Genetic defect;
presumed pathogenesis













Mutation in CD46 : dissociates
C3b and C4b









Mutation in CD59: regulates the
membrane attack complex
formation





Ficolin 3 deficiencya Mutation in FCN3: activates the
classical complement pathway
AR Absence of complement





XL, X-linked inheritance; AR, autosomal recessive inheritance; AD, autosomal dominant inheritance; MAC, membrane attack complex; SLE, systemic lupus
erythematosus; MBP, mannose-binding protein; MASP2, MBP-associated serine protease 2.
aTen or fewer unrelated cases reported in the literature.
New entities added toTable 8 demonstrate the important role of complement regulators in a group of well-described inflammatory disorders. In particular, we have
added mutations in membrane bound as well as surface attached soluble complement regulatory proteins recognized in hemolytic–uremic syndrome, age-related
macular degeneration, and preeclampsia. The connecting theme of these otherwise unrelated clinical events is excessive activation or insufficient regulation of C3;
these events lead to recruitment of leukocytes and permit secretion of inflammatory and anti-angiogenic mediators that disrupt the vascular bed of the target organ.
Alterations in the genes for Factor B (CFB), Factor I (CFI), Factor H (CFH), and CD46 act as susceptibility genes rather than disease causing mutations. Population
studies reveal no detectable increase in infections in MBP (also known at mannose-binding lectin – MBL) deficient adults. The 3MC syndrome, a developmental
syndrome, has been variously called Carnevale, Mingarelli, Malpuech, and Michels syndrome.
Table 9 | Phenocopies of PID.
Disease Genetic defect/
presumed pathogenesis










double negative (DN) T
alpha/beta cells
Normal, but increased













Somatic mutation in KRAS
(gain-of-function)
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Table 9 | Continued
Disease Genetic defect/
presumed pathogenesis






Somatic mutation in NRAS
(gain-of-function)
Increased CD4− CD8−












Germline mutation in AIRE
AutoAb to IL-17 and/or IL-22





















AutoAb to CI inhibitor Normal Normal Normal Angioedema/C1 INH
deficiency (hereditary
angioedema)
The rapid advances in gene identification technology, including
the widespread use of whole exome and whole genome sequenc-
ing, has meant that the ability to identify gene defects in affected
families and even single individuals with inherited diseases has
grown enormously. In this report, over 30 new gene defects have
been added that were identified since the previous classification in
November, 2011. These defects can be found in all major groups
of PIDs included in this report. In many cases, the mutations are
not necessarily in genes formally implicated in immune cell func-
tion but are genes involved in essential cell processes. The more
detailed analysis and functional consequences of such defects as
illustrated by these PIDs will increase our understanding of the
interplay between different cellular processes in the development
and function of the immune system.
Among the newly identified, gene defects are many that are to
date particular to a single pedigree or individual; such defects may
prove exceedingly rare, or indeed may not necessarily be found
to recur in other individuals. We have marked conditions for
which there are 10 or fewer reported individuals with an aster-
isk, although historically, following the description of the first
few cases, additional individuals with a similar PID phenotype
and genotype have often been recognized. It is likely that we will
uncover many more “personal” or very rare gene defects over time
and that the spectrum of PIDs will become increasingly diverse and
complex, due to contributions of both environmental exposures
and genetic modifiers to each affected individual. The value of this
report therefore to capture and catalog the full spectrum at any
one time point becomes increasingly important.
The goal of the IUIS Expert Committee on PIDs is to increase
awareness, facilitate recognition, and promote optimal treatment
for patients with PIDs. In addition to the current report and pre-
vious “classification table” publications, the committee has also
produced a “Phenotypic Approach for IUIS PID Classification
and Diagnosis: Guidelines for Clinicians at the Bedside,” which
aims to lead physicians to particular groups of PIDs starting from
clinical features and combining routine immunological investiga-
tions. Together, these contributions will hopefully allow a practical
clinical framework for PID diagnosis. The committee also aims to
establish a classification of PIDs based on other aspects and will
work on publishing further guidelines in due course.
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